Manipulation of the host protein acetylation network by human immunodeficiency virus type 1.
Over the past 15 years, protein acetylation has emerged as a globally important post-translational modification that fine-tunes major cellular processes in many life forms. This dynamic regulatory system is critical both for complex eukaryotic cells and for the viruses that infect them. HIV-1 accesses the host acetylation network by interacting with several key enzymes, thereby promoting infection at multiple steps during the viral life cycle. Inhibitors of host histone deacetylases and bromodomain-containing proteins are now being pursued as therapeutic strategies to enhance current antiretroviral treatment. As more acetylation-targeting compounds are reaching clinical trials, it is time to review the role of reversible protein acetylation in HIV-infected CD4(+) T cells.
a Gladstone Institute of Virology and Immunology , San Francisco , CA , USA and.|b Department of Medicine , University of California , San Francisco , CA , USA.
Mark Y
MY
Jeng
a Gladstone Institute of Virology and Immunology , San Francisco , CA , USA and.|b Department of Medicine , University of California , San Francisco , CA , USA.
Ibraheem
I
Ali
a Gladstone Institute of Virology and Immunology , San Francisco , CA , USA and.|b Department of Medicine , University of California , San Francisco , CA , USA.
Melanie
M
Ott
D000107:Acetylation; D019380:Anti-HIV Agents / Q000494:pharmacology / Q000627:therapeutic use; D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects / Q000276:immunology / Q000378:metabolism* / Q000821:virology; D004791:Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D015658:HIV Infections / Q000188:drug therapy / Q000276:immunology / Q000378:metabolism* / Q000821:virology; D015497:HIV-1 / Q000187:drug effects / Q000276:immunology* / Q000378:metabolism / Q000472:pathogenicity; D051548:Histone Acetyltransferases / Q000037:antagonists & inhibitors / Q000378:metabolism; D056572:Histone Deacetylase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D006655:Histone Deacetylases / Q000737:chemistry / Q000378:metabolism; D006657:Histones / Q000378:metabolism; D054884:Host-Pathogen Interactions / Q000187:drug effects; D006801:Humans; D007527:Isoenzymes / Q000037:antagonists & inhibitors / Q000378:metabolism; D018448:Models, Immunological; D011499:Protein Processing, Post-Translational / Q000187:drug effects
D019380:Anti-HIV Agents; D004791:Enzyme Inhibitors; D056572:Histone Deacetylase Inhibitors; D006657:Histones; D007527:Isoenzymes; D051548:Histone Acetyltransferases; D006655:Histone Deacetylases
Epigenetic regulation; latency; post-translational modification; therapeutic inhibitors; viral infection; virus–host interactions